CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionParallel Advisors, LLC
Latest Disclosed Ownership619 shares
Latest Disclosed Value $ 32,496
Parallel Advisors, LLC ownership in CRSP / CRISPR Therapeutics AG

On February 11, 2026 - Parallel Advisors, LLC filed a 13F-HR form disclosing ownership of 619 shares of CRISPR Therapeutics AG (US:CRSP) valued at $32,460 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 589 shares of CRISPR Therapeutics AG. This represents a change in shares of 5.09% during the quarter. The current value of the position is $32,238 USD.

Parallel Advisors, LLC has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-11 2025-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 619 30 5.09 32 -15.79 0.0006
2025-11-13 2025-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 589 51 9.48 38 46.15 0.0007
2025-07-08 2025-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 538 31 6.11 26 52.94 0.0005
2025-04-08 2025-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 507 67 15.23 17 0.00 0.0004
2025-02-10 2024-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 440 0 0.00 17 -15.00 0.0004
2024-11-13 2024-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 440 -399 -47.56 21 -55.56 0.0005
2024-08-08 2024-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 839 96 12.92 45 -10.00 0.0012
2024-05-06 2024-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 743 391 111.08 51 127.27 0.0014
2024-02-12 2023-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 352 139 65.26 22 144.44 0.0007
2024-05-20 2023-09-30 13F/A-1 CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 213 20 10.36 10 -10.00 0.0003
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 213 20 10 0.0003
2024-05-20 2023-06-30 13F/A-1 CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 193 0 0.00 11 25.00 0.0003
2023-08-04 2023-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 193 0 11 0.0003
2024-05-20 2023-03-31 13F/A-1 CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 193 -47 -19.58 9 -11.11 0.0003
2023-04-25 2023-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 193 -47 9 0.0003
2023-02-06 2022-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 240 -74 -23.57 10 -57.14 0.0004
2022-11-10 2022-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 314 -3 -0.95 21 10.53 0.0010
2022-08-01 2022-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 317 13 4.28 19 0.00 0.0009
2022-04-28 2022-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 304 -100 -24.75 19 -38.71 0.0008
2022-01-20 2021-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 404 74 22.42 31 -16.22 0.0012
2021-11-02 2021-09-30 13F/A-1 CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 330 -103 -23.79 37 -47.14 0.0015
2021-08-06 2021-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 433 125 40.58 70 84.21 0.0030
2021-04-23 2021-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 308 63 25.71 38 0.00 0.0018
2021-02-02 2020-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 245 245 38 0.0021
2020-07-16 2020-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 0 -557 -100.00 0 -100.00
2020-04-27 2020-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 557 198 55.15 23 4.55 0.0019
2020-01-30 2019-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 359 0 0.00 22 46.67 0.0017
2019-11-01 2019-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 359 0 0.00 15 -11.76 0.0013
2019-08-05 2019-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 359 359 17 0.0017
2018-11-01 2018-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 0 -200 -100.00 0 -100.00
2018-07-30 2018-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 200 200 11 0.0016
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-01-19 2021-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-10-22 2021-09-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock Call 433 70 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.